First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies.
about
Epigenetic polypharmacology: from combination therapy to multitargeted drugsA novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance.CG200745, an HDAC inhibitor, induces anti-tumour effects in cholangiocarcinoma cell lines via miRNAs targeting the Hippo pathway.
P2860
First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
First-in-human study of the to ...... refractory solid malignancies.
@en
First-in-human study of the to ...... refractory solid malignancies.
@nl
type
label
First-in-human study of the to ...... refractory solid malignancies.
@en
First-in-human study of the to ...... refractory solid malignancies.
@nl
prefLabel
First-in-human study of the to ...... refractory solid malignancies.
@en
First-in-human study of the to ...... refractory solid malignancies.
@nl
P2093
P2860
P1476
First-in-human study of the to ...... refractory solid malignancies.
@en
P2093
Hyunju Cha
Jae-Lyun Lee
Jeong-Eun Kim
JoongMyung Cho
Kyu-pyo Kim
Seong Joon Park
Seonggu Ro
Sool-Ki Kwon
Tae Won Kim
Yong Sang Hong
P2860
P2888
P304
P356
10.1007/S10637-015-0262-2
P577
2015-06-17T00:00:00Z